Tests LIV001 for safety in people with mild-to-moderate ulcerative colitis
Tests LIV001 against placebo in adults with mild-to-moderate active ulcerative colitis.
Plain-language title generated from the registry record
Registry title: LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)
Key facts
- Where
- Wroclaw, PolandSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06749795, who can take part
Where in Poland
- Centrum Badan Klinicznych Piotr Napora Lekarze Spolka PartnerskaWroclaw, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Liveome Inc.
- Trial code
- NCT06749795
- Record updated
- 24 March 2025
- Original description
A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative ColitisRead full original descriptionShow less
A Randomized, Double-Blind, Placebo Controlled, Multi -Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis
A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative Colitis
Inclusion: Male or female aged 18 to 65 years (inclusive) at Screening; Established diagnosis of UC for at least 3 months prior to Screening, diagnosed by routine clinical, radiographic, endoscopic or pathologic criteria (Confirmed by colonoscopy and pathology records or, if unavailable, diagnosis confirmed by a letter from the subject's general practitioner.).
Exclusion: History of a condition associated with significant immunosuppression, or chronic administration (> 14 consecutive days) of immunosuppressants or other immune-modifying drugs within 3 months prior to Visit 3 (subjects taking oral medications for UC, including corticosteroids or immunomodulators, are not excluded); Possible or confirmed diagnosis of Crohn's Disease, other form of inflammatory bowel disorder and coeliac disease.